Robert P Hunter
Overview
Explore the profile of Robert P Hunter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hunter R, Randazzo J, Miller P, Paul D, Gould Iii H, Mallozzi R
Am J Vet Res
. 2024 Dec;
86(2).
PMID: 39681070
Objective: The objective of this study was to satisfy the US FDA's Center for Devices and Radiological Health regarding the safety of targeted osmotic lysis (TOL), a novel treatment for...
2.
Krabel B, Foust L, Fuller G, Hunter R
J Vet Pharmacol Ther
. 2024 Feb;
47(4):288-293.
PMID: 38407510
In the United States, a generic Type A medicated article product can gain the FDA approval by demonstrating bioequivalence (BE) to the pioneer product by successfully conducting a blood level,...
3.
Hunter R, Madigan R
J Vet Pharmacol Ther
. 2023 Oct;
47(2):65-72.
PMID: 37818972
This study evaluated four different formulations of itraconazole and amiodarone. Formulation 1 was Vida's combination tablet containing both active pharmaceutical ingredients (APIs). Formulation 2 was separate, commercially available human generic...
4.
Ehrenzweig J, Hunter R
J Am Vet Med Assoc
. 2023 Sep;
261(11):1597-1604.
PMID: 37758186
Alzheimer disease (AD) is the leading cause of dementia among older adults. Current AD treatment options are limited, and the absence of appropriate research animals has significantly hindered the development...
5.
Hunter R, Ehrenzweig J, Hainsworth A, Crawford A, Dagan A, Sage J, et al.
Am J Vet Res
. 2023 Sep;
84(11).
PMID: 37739391
Treatment options for human dementia remain limited, and additional research is needed to develop and validate translational models. Canine cognitive decline (CCD) is common in older dogs and a major...
6.
Gould 3rd H, Edenfield S, Miller P, Sherman K, Melius B, Whitney A, et al.
Case Rep Vet Med
. 2022 Aug;
2022:2747108.
PMID: 35967596
Background: Targeted osmotic lysis (TOL) is a novel technology that involves concomitant stimulation of voltage-gated sodium channels (VGSCs) and the pharmacological blockade of Na, K-ATPase causing lysis of highly malignant...
7.
Hare J, Hunter R, Cantiello M
J Vet Pharmacol Ther
. 2021 Nov;
44(6):993-994.
PMID: 34755368
No abstract available.
8.
Krabel B, Foust L, Fuller G, Foss A, Garner L, Hunter R
J Vet Pharmacol Ther
. 2020 Nov;
44(4):619-627.
PMID: 33206406
In the United States, a generic Type A medicated article (premix) product can gain government approval by demonstrating in vivo bioequivalence (BE) to the pioneer product in a blood level,...
9.
Fayette M, Rose J, Hunter R, Bowman M, Proudfoot J
J Zoo Wildl Med
. 2019 Jul;
50(2):466-469.
PMID: 31260216
Pharmacokinetics study of ceftiofur crystalline free acid (CCFA) was conducted in 14 adult captive smooth dogfish (). A single dose of CCFA at 6.6 mg/kg was administered intramuscularly. Blood samples...
10.
Hunter R, Isaza R
Pharmaceutics
. 2017 Mar;
9(1).
PMID: 28241435
Polypharmacy is a term that describes the inappropriate, concurrent use of multiple drugs in an individual patient. Zoological medicine practitioners must take approved agents (veterinary or human) and extrapolate their...